Dr Reddy's shares remain under pressure after its semaglutide production halt. Here's what leading brokerages expect for earnings, target prices and recovery.

JM Financial keeps Dr Reddy’s at Buy despite semaglutide delay, seeing 23% upside and an FY28 Abatacept catalyst—track the ...

Dr Reddy's now expects to supply 6-7 million semaglutide pens in the second half of 2026-27 (Apr-Mar), lower than its earlier ...

The company said certain batches of semaglutide were found to be out of specification due to issues associated with the API ...

Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide ...

Shares of Dr. Reddy's Laboratories are trading 4.6% higher on Monday at ₹1,413.1. The stock has gained 8.5% so far in the month of June, which has turned out to be its best month since December 2024, ...

An already approved drug has shown promise in preventing rheumatoid arthritis in people with a pre-existing condition that ...

Nomura sees 35% upside for Dr Reddy’s as it pivots to branded consumer health; check if now is the time to buy!

A clinical trial led by researchers from Hospital Clínic de Barcelona, the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC) ...

A one-year course of antirheumatic drug abatacept delayed the onset of rheumatoid arthritis for up to four years among patients at high risk of the condition. The corresponding study was published in ...

Dr Reddy’s Laboratories announced that the US Food and Drug Administration (FDA) has accepted for review, its 351 (k) Biologics License Application (BLA) IV for infusion formulation for DRL_AB, a ...